Automatic Web Traffic Generator


US   France   Germany   Spain   Netherlands  

Study Of Varlitinib For Firstline Gastric Cancer Treatment Misses Primary Endpoint | AutoTraffic

Study of varlitinib for first-line gastric cancer treatment misses primary endpoint

A phase 2 study designed to compare varlitinib with placebo as first-line treatment for certain patients with gastric cancer failed to meet its primary endpoint of significant reduction in tumor size ... read more

Varlitinib Misses Primary Endpoint in Frontline Gastric Cancer Trial

The FDA granted varlitinib an orphan drug designation in gastric cancer and cholangiocarcinoma in June 2016 and April 2015, respectively, and was granted orphan drug designation for the treatment ... ... read more

ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

evaluating its pipeline candidate — varlitinib — for the treatment of first-line gastric cancer, failed to meet the primary endpoint of showing significant reductions in tumor size. The study ... read more

ASLAN Pharma's varlitinib flunks mid-stage gastric cancer study

varlitinib in patients with HER1/HER2-positive advanced/metastatic gastric cancer failed to achieve the primary endpoint. Specifically, first-line treatment with varlitinib, a pan-HER inhibitor ... read more

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

In the recently completed study, varlitinib did not meet the primary endpoint of significant reductions in tumour size after 12 weeks of treatment ... ASLAN Pharmaceuticals, said: “First-line gastric ... read more

Trial Alert: ASLAN Pharma's Phase II Gastric Cancer Study Fails

phase II clinical study of Varlitinib as first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients has failed to meet the primary endpoint of significant reductions ... read more

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer Taiwan Stock Exchange:6497.TWO

In the recently completed study, varlitinib did not meet the primary endpoint of significant reductions in tumour size after 12 weeks of treatment ... ASLAN Pharmaceuticals, said: 'First-line gastric ... read more

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

In the recently completed study, varlitinib did not meet the primary endpoint of significant reductions in tumour size after 12 weeks of treatment ... said: “First-line gastric cancer is ... read more
Subscribe to RSS Feed
Popular RSS Feeds: 0800 numbers word cloud generator syndra counters can you tattoo over stretch marks paul rodriguez jr transcription where is the nearest coffee shop bryant lake bowl average car insurance rates iis server coastal pediatrics free online poker trist counters communications degree personal injury lawyer albuquerque commie subs shing banc home loans aperture app alan harper macau slot west salem high school

Buy AutoTrafficRSS script now for only $27!

We will send the script to your PayPal email within few hours,
Please add FullContentRSS@gmail.com to your email contact.



Auto Traffic generator Powered by. Full RSS Feed | Article Generator | Contact Us